Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-90010 PK/PD in Preoperative Glioma
NCT04047303Phase 1Terminated
- Sponsor
- Celgene Corporation
- Start
- Jan 2020
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of trotabresib in astrocytoma and glioblastoma (GBM), sponsored by Celgene Corporation. Primary endpoints: Intratumoral concentration of CC-90010 in tumor tissue, Area under the plasma concentration-time curve from time zero to 24 hours and 6 more. Started Jan 2020; status: terminated.
02
Drugs
trotabresib
03
Conditions
astrocytomaglioblastoma (GBM)
Beyond the preview
Go deeper on NCT04047303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04047303.